Skip to content

Effect of SNB on the QoR in Patients Undergoing Supratentorial Tumor Resection

Effect of Scalp Nerve Block on the Quality of Recovery in Patients Undergoing Supratentorial Tumor Resection

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06157359
Enrollment
84
Registered
2023-12-05
Start date
2023-11-14
Completion date
2024-10-31
Last updated
2024-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Analgesia, Quality of Recovery, Supratentorial Tumor, Craniotomy, Scalp Nerve Block

Keywords

Supratentorial tumor resection, Scalp nerve block, quality of recovery, postoperative analgesia

Brief summary

Patients with Supratentorial tumor undergoing craniotomy have a higher risk of postoperative pain, which will affect their postoperative quality of recovery (QoR). Although scalp nerve block (SNB) can alleviate postoperative pain, the effect on postoperative QoR in patients with supratentorial tumor undergoing craniotomy is still unclear. This study is aimed to explore the effect of SNB on postoperative QoR in this population. To explore the effect, we design a randomized controlled trial in which 84 patients with supratentorial tumor will be randomly assigned to either the SNB group or control group. The primary outcome is 15-item QoR score at 24 h after surgery. The secondary outcomes include 15-item QoR scores at 72 h after surgery, Riker Sedation-Agitation Scale, nausea and vomiting, intraoperative opioids and propofol consumption, perioperative heart rate and mean artery pressure, the duration of anesthesia and surgery, time to extubation, PACU duration, the length of postoperative days, adverse events within 72h and total medical expenses.

Interventions

In the SNB group, bilateral scalp nerve blocks will performed using 20 mL of 0.75% ropivacaine after anesthesia induction. To cover the area of surgical incision and skull clamp, seven scalp nerves including the supratrochlear, supraorbital, zygomaticotemporal, auriculotemporal, lesser occipital and greater occipital nerves, are blocked bilaterally by injecting 1-2 ml of the solution using a 25-gauge needle.

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* age between 18 and 65; * the diagnosis was supratentorial tumor; * scheduled for elective supratentorial craniotomy with general anesthesia ; * the American Society of Anesthesiologists physical status I-III;

Exclusion criteria

* the BMI≦18kg/m2 or BMI≧30kg/m2; * refusing to sign written informed consent; * anticipated surgery duration is too short (\<2 h) or too long (\>6 h); * liver or kidney dysfunction, severe cardiopulmonary failure or nervous system disease ; * with other malignancies ; * severe hematological disease and / or abnormal coagulation function; * fever, systemic and / or scalp infection; * tumors are metastases, aneurysms, hemangioma, or located in the skull base, or located in functional brain areas such as language and movement; * allergy to any drug used in this study; * a history of craniotomy tumor resection; * preoperative usage of antiinflammatory agents or analgesics; * pregnant women, lactating women, illiterate people, people with cognitive impairment, a history of mental illness, unable to communicate and complete the scale assessment; * patients with severe hemodynamic disturbances or other life-threatening complications during the operation, or those transferred to the intensive care unit (ICU) after surgery.

Design outcomes

Primary

MeasureTime frameDescription
the 15-item QoR score at 24 hours after surgeryup to day1 after surgeryThe quality of postoperative recovery is assessed by QoR-15 on the first day after operation.

Secondary

MeasureTime frameDescription
postoperative pain scoresup to day3 after surgeryPain intensity is evaluated with the numerical rating scale (0-10, 0 = no pain, 10 = unbearable pain) at 6 time points: 20 minutes after extubation, discharge from PACU, 6 hours, 12 hours, 24 hours, and 72 hours following surgery. The worst pain score during each interval is recorded.
Riker Sedation-Agitation Scaleduring in PACU, an average of 3 hoursRiker Sedation-Agitation Scale is assessed at 2 time points: 20 minutes after extubation and discharge from PACU.
nausea and vomitingup to day3 after surgeryNausea and vomiting is assessed by postoperative nausea and vomiting score (0, no nausea or vomiting; 1, nausea but no vomiting; 2, vomiting once or twice; 3, vomiting on more than two occasions) at 3 time points: discharge from PACU, 24 hours, and 72 hours after operation.
opioids and propofol consumptionduring operation and in PACU, an average of 8 hoursTotal drug dose of sufentanil, remifentanil and propofol consumption is recorded during operation and in PACU.
the 15-item QoR score at 72 hours after surgeryup to day3 after surgeryThe quality of postoperative recovery is assessed by QoR-15 on the third day after operation.
time to critical eventsduring hospitalization, an average of 10 daysThe time to critical events are recorded, including the duration of anesthesia and surgery, time to extubation, PACU duration, postoperative hospital days and so on.
adverse eventsup to day3 after surgeryAdverse events within 72 hours after operation are recorded.
total medical expensesduring hospitalization, an average of 10 daysThe total medical expenses is recorded during hospitalization.
mean artery pressure and heart rateduring operation and in PACU, an average of 8 hoursMean artery pressure and heart rate are recorded at 6 time points: before anesthesia induction (T0), after placement of the skull clamp (T1), beginning of surgery (T2), end of surgery (T3), 20 minutes after extubation (T4) , and discharge from PACU (T5).

Countries

China

Contacts

Primary ContactLina Yu, doctor
zryulina@zju.edu.cn+8613958033387

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026